Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan (R): Results of a 28 day, double masked, randomized, active comparator study in open angle glaucoma (OAG) and ocular hypertension (OHT)

Miller-Ellis Eydie G.; Berlin Michael S.; Ward Caroline L.; Sharpe John; Jamil Alam; Harris Alon

首页> 外文期刊>Investigative ophthalmology & visual science >Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan (R): Results of a 28 day, double masked, randomized, active comparator study in open angle glaucoma (OAG) and ocular hypertension (OHT)

【24h】

Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan (R): Results of a 28 day, double masked, randomized, active comparator study in open angle glaucoma (OAG) and ocular hypertension (OHT)

机译：新型双EP3 / FP受体激动剂的眼睛低血压效应和耐受性ONO-9054与Xalatan（R）：28天，双掩盖，随机，活性比较器的结果，开放角度青光眼（OAG）和眼高血压（OHT））

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Investigative ophthalmology & visual science》 |2016年第12期|共3页
作者
Miller-Ellis Eydie G.; Berlin Michael S.; Ward Caroline L.; Sharpe John; Jamil Alam; Harris Alon;
展开▼
作者单位

Scheie Eye Inst Ophthalmol Philadelphia PA USA;

Glaucoma Inst Beverly Hills CA USA;

Ono Pharma Cambridge England;

Ono Pharma Cambridge England;

Ono Pharma Cambridge England;

Indiana Univ Sch Med Indianapolis IN 46202 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
专利

1. Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan (R): Results of a 28 day, double masked, randomized, active comparator study in open angle glaucoma (OAG) and ocular hypertension (OHT) [J] . Miller-Ellis Eydie G., Berlin Michael S., Ward Caroline L., Investigative ophthalmology & visual science . 2016,第12期

机译：新型双EP3 / FP受体激动剂的眼睛低血压效应和耐受性ONO-9054与Xalatan（R）：28天，双掩盖，随机，活性比较器的结果，开放角度青光眼（OAG）和眼高血压（OHT））
2. Tolerability, Safety and Pharmacokinetics of ONO-9054, a novel FP/EP3 dual receptor agonist: a 14 day study in subjects with ocular hypertension or open angle glacoma [J] . Cheryl L Rowe-Rendleman, Akifumi Fujii, Takafumi Ouchi, Investigative ophthalmology & visual science . 2014,第13期

机译：新型FP / EP3双受体激动剂ONO-9054的耐受性，安全性和药代动力学：在高眼压或开角型青光眼患者中进行的14天研究
3. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study [J] . Berlin Michael S., Rowe-Rendleman Cheryl, Ahmed Ike, British journal of ophthalmology . 2016,第6期

机译：早或晚向开角型青光眼或高眼压症患者使用EP3 / FP双受体激动剂ONO-9054：一项随机交叉研究的结果
4. Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day double-masked randomised study [O] . Eydie Miller Ellis, Michael S Berlin, Caroline L Ward, -1

机译：新型EP3 / FP激动剂ONO-9054与Xalatan的降眼压作用：一项为期28天双掩蔽随机研究的结果
5. Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study [O] . Ellis, Eydie Miller, Berlin, Michael S., Ward, Caroline L., 2016

机译：新型EP3 / FP激动剂ONO-9054与Xalatan的降眼压作用：一项为期28天，双掩蔽，随机研究的结果

Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan (R): Results of a 28 day, double masked, randomized, active comparator study in open angle glaucoma (OAG) and ocular hypertension (OHT)

著录项

相似文献

相关主题

期刊订阅